, and the preparation process and uses
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 11, 2014
Grant Date -
May 16, 2013
app pub date -
Mar 21, 2012
filing date -
Nov 15, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
What is disclosed in the invention is a preparation method of a supercritical Cinnamomum subavenium extract, which is made from the material, the dried stem of C. subavenium. The extract is obtained by extracting C. subavenium which is pulverized as particles with supercritical carbon dioxide fluid. The C. subavenium extract or its active ingredient, subamolide A, can be used to inhibit the growth of human urothelial carcinoma cell lines. In addition, the C. subavenium extract (or subamolide A) is able to synergistically inhibit the growth of human urothelial carcinoma cell lines with cisplatin (CDDP) or gemcitabine (Gem). Therefore, the C. subavenium extract (or subamolide A) can be an anticancer drug alone, or forms a pharmaceutical composition with CDDP (or Gem) to treat with cancers in respect of urinary system.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully